Diabetes and COVID-19: a bitter nightmare

被引：0

作者：

Mandana Hasanzad

Bagher Larijani

Hamid Reza Aghaei Meybodi

机构：

[1] Tehran Medical Sciences,Medical Genomics Research Center

[2] Islamic Azad University,Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute

[3] Tehran University of Medical Sciences,Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute

[4] Tehran University of Medical Sciences,Evidence Based Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute

[5] Tehran University of medical Sciences,undefined

来源：

Journal of Diabetes & Metabolic Disorders | 2022年 / 21卷

关键词：

COVID-19; SARS-CoV-2; Hyperglycemia; Diabetes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Initial studies found a bidirectional interaction between coronavirus disease 2019 (COVID-19) and diabetes. In this article we intend to review the association and consequences of COVID-19 in the future of diabetes in case of prevalence and treatment. There is substantial evidence that COVID-19 may result in the new-onset of hyperglycaemia. Therefore, it seems that COVID-19 will change the predictions for the prevalence of diabetes. Moreover, it raises numerous challenges for the clinical management of diabetes. In COVID-19 patients, new-onset hyperglycemia is associated with a poor prognosis. Diabetes mellitus and other comorbidities should be strictly controlled. But, with the emergence of COVID-19 disease, the future of diabetes mellitus in terms of prevalence and treatment will change and policymakers should consider developing new management strategies in this regard.

引用

页码：1191 / 1193

页数：2

共 26 条

[1]

Codo AC(2020)Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis Cell Metab 32 437-46

[2]

Davanzo GG(2006)Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS Diabet Med 23 623-8

[3]

de Brito Monteiro L(2020)Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19 Diabetes Res Clin Pract 167 108382-35

[4]

de Souza GF(2018)Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study Diabetes Care 41 2127-30

[5]

Muraro SP(2021)COVID-19 and diabetes mellitus: from pathophysiology to clinical management Nat Rev Endocrinol 17 11-76

[6]

Virgilio-da-Silva JV(2017)Metformin: historical overview Diabetologia 60 1566-9

[7]

Yang J(2017)Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes Diabetologia 60 1620-undefined

[8]

Feng Y(undefined)undefined undefined undefined undefined-undefined

[9]

Yuan M(undefined)undefined undefined undefined undefined-undefined

[10]

Yuan S(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 →